Inhibin

What is Inhibin?

Inhibin is a family of endogenous dimeric glycoprotein hormones produced primarily by ovarian granulosa cells in women and testicular Sertoli cells in men. It exists as two biologically active forms: Inhibin A (an alpha subunit linked to a beta-A subunit) and Inhibin B (an alpha subunit linked to a beta-B subunit). Both are members of the TGF-β superfamily and share their beta subunits with their sister molecule activin, which exerts the opposite effect. Inhibin's defining physiologic role is selective negative-feedback suppression of pituitary follicle-stimulating hormone (FSH) secretion, with minimal direct effect on luteinizing hormone (LH) — the feature that distinguishes it from estradiol's broader feedback on the hypothalamic-pituitary-gonadal axis. Clinically, inhibin is not used as a therapeutic; it is used as a serum biomarker for ovarian reserve assessment, granulosa cell tumor diagnosis and monitoring, second-trimester Down syndrome screening, and male fertility workup.

What Inhibin Is Investigated For

Inhibin's clinical utility is almost entirely as a biomarker, not a therapy. The strongest-evidence uses are well-established clinical assays: serum inhibin (particularly Inhibin B) is a highly sensitive and specific marker for adult-type granulosa cell tumors of the ovary — used both for initial diagnosis and for detecting recurrence, often months before imaging; dimeric Inhibin A is one of the four analytes in the second-trimester maternal serum quad screen for Down syndrome; and serum Inhibin B is the single best endocrine marker of spermatogenesis in subfertile men, outperforming FSH for discriminating competent from impaired sperm production. The moderate-evidence uses include ovarian reserve assessment, where Inhibin B was historically used but has largely been superseded by anti-Müllerian hormone (AMH) and antral follicle count, and pediatric endocrinology applications such as differentiating constitutional delayed puberty from congenital hypogonadotropic hypogonadism in boys. Critically, inhibin is an endogenous biomarker measured in standard reference laboratories — there is no therapeutic exogenous inhibin product on the market, no research-chemical inhibin peptide circulating in the community use context, and no dosing or administration protocol for it. Discussion of inhibin at the consumer level is entirely about understanding lab-test results, not about taking a drug.

History & Discovery

The concept of inhibin considerably predates its molecular identification, and the clock the field runs on starts in 1923, not 1932 — which is why the standard historical review is titled 'Inhibin at 90' and was published in 2014. In 1923, J.C. Mottram and W. Cramer reported in the Quarterly Journal of Experimental Physiology that treating the testes with radium produced hypertrophy of the anterior pituitary, visible as castration cells; vasectomy prevented the change, pointing at the seminiferous tubules specifically rather than the testis as a whole. Nine years later, in 1932, D. Roy McCullagh published a paper in Science postulating a non-steroidal, water-soluble testicular substance that prevented pituitary hypertrophy and hyperplasia in rats, and named it 'inhibin' for its inhibitory effect on pituitary gonadotrophs. He correctly inferred that this factor was distinct from the androgens known at the time, because aqueous testicular extracts (which lacked lipid-soluble androgens) still blunted the castration-induced pituitary response. The hypothesis was then largely doubted for forty years; the modern era only began around 1972. McCullagh's hypothesis was essentially correct, but the molecule itself eluded purification for more than fifty years — a striking gap in which inhibin existed as a predicted-but-unisolated entity while reproductive endocrinology advanced around it. The molecular era of inhibin began in the mid-1980s with a burst of structural work on ovarian follicular fluid as the source material. Four groups published purifications of inhibin from bovine and porcine follicular fluid in 1985 alone — Ling, Miyamoto, Rivier, and Robertson — with Nicholas Ling and Wylie Vale at the Salk Institute and David Robertson and David de Kretser in Melbourne the most durable names in the Western literature. Henry Burger, also in Melbourne, was central to translating the molecule into a clinical tumour marker rather than to the purification itself. In 1985, A.J. Mason and colleagues in a Genentech–Salk Institute collaboration cloned cDNAs encoding both the alpha and beta subunits of porcine inhibin, reported in Nature — demonstrating that inhibin is a heterodimer of an alpha subunit and one of two beta subunits, and that the beta subunits showed striking homology to transforming growth factor-beta. This placed inhibin in what is now recognized as the TGF-β superfamily, alongside activins, BMPs, GDFs, and the TGF-β isoforms themselves, and launched the modern molecular era of the field. The years immediately following brought activin (discovered in 1986 as a dimer of inhibin beta subunits without an alpha subunit, with the functionally opposite effect on FSH) and follistatin (discovered in 1987 as an activin-binding protein). By 1992, Martin Matzuk and colleagues at Baylor published the inhibin-alpha knockout mouse in Nature, demonstrating that every homozygous knockout developed gonadal stromal tumors and establishing inhibin as the first secreted protein with tumor-suppressor activity — providing the mechanistic rationale for what would become the clinical use of serum inhibin as a granulosa cell tumor biomarker. Over the 1990s and 2000s, development of specific dimeric Inhibin A and Inhibin B immunoassays brought the molecule into routine clinical laboratory use in granulosa cell tumor monitoring, prenatal Down syndrome screening, ovarian reserve assessment, and male fertility workup.

How It Works

Inhibin is your body's way of telling the brain to stop asking the gonads for more effort. Your ovaries or testes make it when they're working well, and it travels to the pituitary gland, where it turns down the pituitary's output of FSH — the hormone that stimulates egg follicle development or sperm production. If the gonads start failing, inhibin drops, FSH rises, and the brain ramps up its signaling. Measuring inhibin in blood is a way of hearing directly from the gonad how well it's working.

Inhibin is a heterodimer of an alpha subunit (encoded by INHA) linked by a disulfide bond to either a beta-A subunit (INHBA) or a beta-B subunit (INHBB), forming Inhibin A or Inhibin B respectively. Both forms are members of the TGF-β superfamily and share their beta subunits with activin, which is a homodimer or heterodimer of beta subunits alone. At the pituitary, activin binds type II activin receptors (ActRII/ActRIIB) and recruits type I receptors (ALK4) to activate Smad2/3-mediated transcription of FSH-beta and stimulate FSH synthesis and secretion. Inhibin does not have its own dedicated signaling pathway in the classical sense — instead, it acts as a competitive antagonist of activin by binding ActRII receptors — with much lower affinity than activin itself, which is why the co-receptor matters so much — in a complex facilitated by the TGF-β type III receptor betaglycan (TGFBR3), which acts as a co-receptor and markedly strengthens inhibin's ability to sequester ActRII away from activin. Where betaglycan is present, inhibin can also antagonize bone morphogenetic proteins whose signaling depends on access to type II activin receptors — a reach beyond the FSH axis that is easy to miss if inhibin is thought of purely as an activin decoy. The net pituitary effect is selective suppression of FSH-beta transcription with minimal effect on LH, distinguishing inhibin-mediated feedback from estradiol-mediated feedback which acts on both gonadotropins. Production is tissue- and cell-type-specific: ovarian granulosa cells produce both Inhibin A and Inhibin B (with cycle-phase variation), Sertoli cells produce almost exclusively Inhibin B in coordination with germ-cell development, the placenta produces large quantities of Inhibin A in pregnancy, and the adrenal cortex produces small amounts of inhibin subunits whose physiologic role is less well defined.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Inhibin:

• 01Assay standardization — commercial dimeric Inhibin A and Inhibin B immunoassays use different antibody pairs and calibrators, producing non-interchangeable absolute values across platforms and complicating multi-center research and cross-laboratory clinical interpretation.
• 02Inhibin B as a male contraceptive target — selective FSH suppression without LH suppression is pharmacologically attractive for male hormonal contraception, but no inhibin-based or inhibin-mimetic contraceptive has advanced beyond early-phase development.
• 03Role of inhibin in adrenal and extra-gonadal tissues — inhibin subunits are expressed in the adrenal cortex, pituitary, and placenta in ways not fully explained by the gonadal-feedback paradigm, and the functional significance of this extra-gonadal expression is incompletely understood.
• 04Integration with AMH in ovarian reserve testing — whether Inhibin B retains clinical utility alongside or in addition to AMH and antral follicle count, or whether it has been effectively replaced, varies by practice setting. A 2026 diagnostic-accuracy meta-analysis found only moderate accuracy for reserve and lower accuracy for response, concluding Inhibin B is complementary rather than competitive with AMH — which leaves open the narrower and more useful question of whether it adds anything at the margin, in which patients, and at what thresholds.
• 05Inhibin in male hypogonadotropic hypogonadism recovery — whether Inhibin B trajectories during induction of puberty or fertility restoration provide incremental prognostic information beyond FSH, LH, testosterone, and testicular volume is not fully resolved.
• 06Tumor-biomarker utility beyond granulosa cell tumors — the performance of inhibin as a marker for other sex cord-stromal tumors, mucinous ovarian cancers, and rare adrenal tumors is less well characterized than for the classical adult-type granulosa cell tumor use case.
• 07Use as a gonadotoxicity biomarker in pediatric oncology — a 2026 study correlated Inhibin B with cyclophosphamide equivalent dosing in adolescent male childhood-cancer survivors, supporting its role in monitoring spermatogenic damage from alkylating chemotherapy. A 2026 prospective longitudinal study tempers the picture usefully: in pubertal boys treated for hematological malignancies, the seminiferous tubular dysfunction signalled by rising FSH and falling Inhibin B was transient, with recovery by three years after treatment. The optimal monitoring schedule, decision thresholds, and link to adult fertility outcomes are still not standardized, and a single early Inhibin B is clearly the wrong basis for a prognosis.
• 08Inhibin B as a surgical-outcome endpoint — a 2026 meta-analysis found serum Inhibin B significantly higher after orchiopexy for cryptorchidism than before (mean difference 14.03 pg/mL, 95% CI 4.05–24.01), which is a measurable endocrine recovery signal, but whether the size of that rise predicts adult fertility, and what it should change about surgical timing, is unestablished.
• 09Intrafollicular versus serum inhibin — a 2026 study found follicular-fluid follistatin and Inhibin B associated with favourable intermediate IVF outcomes, but the associations did not survive multiple-comparison adjustment, and it remains unclear whether local follicular concentrations carry information that a serum draw does not.
• 10Inhibin B interpretation in PCOS and obesity — a 2026 systematic review and meta-analysis examined the effect of obesity on AMH and Inhibin B levels in PCOS; how Inhibin B should be interpreted in PCOS workup and ovarian-reserve assessment in obese populations remains under active investigation.

Forms & Administration

Inhibin is not administered as a therapeutic. Clinically it is measured in serum by immunoassay — most commonly as dimeric Inhibin A or dimeric Inhibin B, using commercial ELISA-based kits (Beckman Coulter Access, Ansh Labs and others; the legacy DSL inhibin assays passed to Beckman Coulter when it acquired Diagnostic Systems Laboratories in 2005, so a lab report naming DSL is citing a brand that no longer exists independently). Sample handling requirements — time to separation, freezing, and tolerance for hemolysis — vary by platform and are specified in each manufacturer's insert rather than being uniform across assays. Reference ranges are sex-specific, age-specific, and in women cycle-phase-specific; they also differ between assay platforms, and results from different laboratories should not be compared directly.

Common Questions

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions